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Abstract
Background: Human noroviruses (NoVs) are the main cause of gastroenteritis worldwide. The most commonly
detected NoV strains belong to the genetically diverse GII.4 genotype, with new pandemic variants emerging
periodically. Despite extensive efforts, NoV investigation has been hampered by the lack of an effective in vitro cell
culture system. However, NoV-derived recombinant virus-like particles (VLPs) resembling empty capsids are good
surrogates for analysing NoV antigenicity and virus-ligand interactions. NoV VLPs have been reported to bind to
histo-blood group antigens (HBGAs). We have analysed the ability of NoV VLPs derived from GI.1 genotype and
from three GII.4 genotype variants, GII.4-1999, GII.4-2004 and GII.4-2006b, to bind to porcine gastric mucin (PGM),
human saliva and differentiated human intestinal Caco-2 cells (D-Caco-2 cells).
Results: Distinct patterns of saliva binding with the NoV GII.4 variant VLPs were observed, although they bound to
D-Caco-2 cells independently of the expression of HBGAs. Monoclonal antibodies against Lewis antigens were able
to block the binding of NoV VLPs to saliva, but not to D-Caco-2 cells. Blocking HBGAs on the surface of D-Caco-2
cells with specific monoclonal antibodies did not affect NoV VLP binding to cellular membranes. Co-localisation of
Lewis y (Ley) and H-type 2 antigens with NoV VLPs was not observed by immunofluorescence assays.
Conclusion: Although the binding of NoV VLPs of GII.4 genotype variants to human saliva samples occur with distinct
HBGA binding patterns and can be blocked by antibodies against Lewis antigens, their attachment to D-Caco-2 cells
can be mediated by other receptors, which still need further investigation.
Keywords: Human norovirus (NoV), Virus-like particles (VLPs), Caco-2 cells, GII.4 genotype, Histo-blood group antigens
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Background
Noroviruses (NoVs) are the main cause of sporadic cases
and outbreaks of acute gastroenteritis and are associated
with a large burden of disease globally [1–3]. NoVs are
small, non-enveloped, icosahedral viruses with a positive
single-stranded RNA genome; they belong to the Calici-
viridae family and are genetically classified into 6 gen-
ogroups (GI-GVI) with a recently proposed genogroup
VII [4], although genogroup I (GI) and GII cause most
human NoV infections. Despite this diversity over the
past two decades most reported NoV outbreaks and
epidemics have been caused by NoV GII.4 genotype.
Phylogenetic analyses of the GII.4 strains circulating in
the last 20 years have shown that this genotype can be
divided into distinct variants, which peak and wane over
time in a similar pattern to that described for influenza
viruses [5–7]. Several studies have linked NoV suscepti-
bility to histo-blood group antigens (HBGAs), namely
with the secretor status associated with the presence of
at least one functional FUT2 allele, and with Lewis anti-
gens (Lea and Leb), determined by the FUT3 gene [8, 9].
The HBGAs, including the ABO, secretor and Lewis
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families, are distributed on cell membranes and mucosal
epithelia with high polymorphism. HBGAs are synthe-
sized from various disaccharide precursors through
sequential additions of monosaccharides with specific
linkages catalysed by different glycosyltransferases [10].
The syntheses of the secretor, Lewis and ABO antigens
are catalyzed by an α-1,2 fucosyltransferase (FUT2), an
α-1,3 or α-1,4 fucosyltransferase (FUT3) and two glyco-
syltransferases (A and B enzymes), respectively. Homo-
zygote carriers of inactive FUT3 alleles essentially lack
Lea and Leb antigens; such individuals are denoted
Lewis-negative and constitute about 5 % of the Cauca-
sian population. Secretor-positive individuals express Leb
antigen, while secretor-negative individuals express Lea
antigen [11]. Human NoVs are known to recognize
HBGAs as attachment factors, with different NoV strains
showing different properties regarding the ability to bind
to different antigens [8, 10].
The NoV genome is organized in three open reading
frames (ORFs). The VP1, encoded by ORF2, is the major
capsid protein, which is further organized into the
N-terminal (N), the shell (S), and the protruding (P)
domains. The P domain is divided into two subdo-
mains: P1 and P2 [12]. The P1 subdomain forms the
anchoring portion of the P dimer connecting it to
the S domain, while the P2 subdomain is exposed on the
surface of the capsid protein and is the most variable
region of the virus. The main epitopes for immunorecog-
nition and the histo-blood group antigen (HBGA) binding
domains reside within this P2 subdomain. The emergence
and accumulation of mutations along the P2 subdomain is
the main driver of evolution for GII.4 strains, which
results in epidemic strains with altered antigenicity and
HBGA binding properties [13–16]. It has been reported
that NoVs attach to either HBGA expressed on the gastro-
duodenal epithelial cells of secretor-positive individuals
[17, 18]. Human secretor positive saliva and synthetic
HBGAs have been used in VLP binding and/or blocking
assays in different studies [19–21]. However, it has also
been shown that NoV can bind to enterocytes independ-
ently of HBGAs [22]. Human NoVs have for long time
been elusive to propagation in cell cultures [23, 24],
although it has been recently reported that human NoVs
can infect B lymphocytes in the presence of HBGA-
expressing bacteria [25]. Caco-2 cells, originally derived
from a human colonic adenocarcinoma, show morpho-
logic and physiologic markers of differentiation character-
istic of the mature small intestine enterocytes, express
carbohydrates of the histo-blood group family on their
surface, and allow significant attachment of norovirus
VLPs mainly when these cells are differentiated [26].
In this study we have assessed the binding properties
of VLPs of different variants of NoV GII.4 genotype to
Caco-2 cells. Moreover, blockade activity of the VLP
binding by porcine gastric mucin (PGM) and monoclo-
nal antibodies (mAbs) against NoV VLPs, anti-Lewis an-
tigens (Lea, Leb, Lex and Ley) or anti-H antigens (H1 and
H2) mAbs was investigated in order to better under-
stand the interactions between NoVs and the cellular
surface of intestinal cells.
Results
Distribution of Lewis antigens, secretor status and ABO
types among the saliva donors
Lewis antigens, secretor status (FUT2) and ABO blood
group of the 22 saliva donors were determined to analyse
the VLP binding patterns. By ABO typing, 10 subjects
were type A, 5 type B, 7 type O and none of them were
type AB. According to the secretor status, 86.4 % (19/22)
were secretors, 22.7 % (5/22) were secretor homozygous
(SeSe), 63.6 % (14/22) were secretor heterozygous (Sese),
and the remaining 13.6 % (3/22), were non-secretors
(sese). The anti-Lewis antigen mAb-based EIA classified
the saliva samples into four groups according to Lewis an-
tigens patterns: Lea+ b+/Le x- y+ (77.3 %), Lea+ b+/Le x+ y+
(4.5 %), Lea+ b-/Lex+ y- (13.6 %) and Lea- b-/Lex- y+ (4.5 %)
(Table 1).
Table 1 Distribution of ABO types, secretor status (FUT2), and
Lewis antigens among 22 saliva donors
Saliva sample Sex Age ABO types FUT2 Lewis antigens
1 M 64 A se-se- Lea+Leb-/Lex+Ley-
2 F 8 A se-se- Lea+Leb-/Lex+Ley-
3 F 31 B se-se- Lea+Leb-/Lex+Ley-
4 F 63 A Se + Se+ Lea+Leb+/Lex-Ley+
5 F 39 A Se + se- Lea+Leb+/Lex-Ley+
6 M 37 A Se + se- Lea+Leb+/Lex-Ley+
7 F 32 A Se + se- Lea+Leb+/Lex-Ley+
8 F 27 A Se + se- Lea+Leb+/Lex-Ley+
9 F 43 A Se + se- Lea+Leb+/Lex-Ley+
10 F 48 A Se + se- Lea-Leb-/Lex-Ley-
11 M 38 A Se + se- Lea+Leb+/Lex-Ley+
12 F 47 B Se + Se+ Lea+Leb+/Lex-Ley+
13 M 58 B Se + se- Lea+Leb+/Lex-Ley+
14 M 31 B Se + Se+ Lea+Leb+/Lex-Ley+
15 M 26 B Se + se- Lea+Leb+/Lex-Ley+
16 M 34 O Se + se- Lea+Leb+/Lex-Ley+
17 F 28 O Se + se- Lea+Leb+/Lex-Ley+
18 M 49 O Se + se- Lea+Leb+/Lex+Ley+
19 F 47 O Se + se- Lea+Leb+/Lex-Ley+
20 M 30 O Se + se- Lea+Leb+/Lex-Ley+
21 F 27 O Se + Se+ Lea+Leb+/Lex-Ley+
22 F 27 O Se + Se+ Lea+Leb+/Lex-Ley+
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NoV VLP binding to porcine gastric mucin (PGM)
All VLPs (GII.4-v0, GII.4-v2 and GII.4-2006b) bound
to PGM. Binding was detected with the anti-NoV
rabbit antiserum (pAb) and no binding differences
were observed among the three variants tested. VLP
binding to PGM was specific, since no reactivity was
detected in the control wells (Fig. 1).
NoV VLP binding to saliva: different strains show distinct
binding patterns determined by HBGAs
Binding assays to saliva were performed to analyse the
NoV VLP binding patterns using saliva from non-
secretors (n = 3) and secretors (n = 19) that were also
divided in 3 groups depending on their blood group
types (A, B and O). Four recombinant NoV VLP variants
representing genogroups I and II were analysed: GI.1
(Norwalk virus), GII.4-1999 (v0), GII.4-2004 (v2) and
GII.4-2006b. Although a limited number of samples
were tested, a clear distinction between secretors and
non-secretors was observed, since the saliva from non-
secretors bound very inefficiently any of the VLPs
(Fig. 2). The results of the binding assay to the saliva
from secretor positive donors indicated that human
NoV genogroups I and II exhibit distinct HBGA binding
patterns (Fig. 2). GI.1 bound more efficiently to saliva
from blood type A and O donors than to type B saliva
samples, GII.4-v0 and v2 variants recognized samples
from all blood groups (A, B and O) and GII.4-2006b
VLPs recognized more efficiently saliva samples from
blood group B donors.
NoV VLP binding to saliva is inhibited by pre-incubation
with anti-Lewis and anti-NoV mAbs
Incubation of secretor (SeSe, O-type, Lea+Leb+/Lex-Ley+)
saliva-coated wells with anti-Ley or anti-Leb resulted in
blocking of the binding of all GII.4 VLP variants to
saliva, with an additive effect observed when anti-Leb
and anti Ley were used in combination, resulting in 60
to 75 % reduction in the binding of the different NoV
VLP variants when compared to untreated wells (Fig. 3).
Anti-Lea or anti-Lex alone or in combination did not
strongly block the binding to secretor saliva samples.
Anti-NoV mAbs tested prevented the binding of their
homologous NoV VLPs to the saliva from an O blood
group individual. Complete binding inhibition was seen
when the mAbs were used up to a 1:200 dilution, whereas
the blocking activity of anti-v2 mAb sharply drop out at
1:400 dilution and the anti-v0 and anti-2006b mAbs
blocked the binding till higher dilutions (Fig. 4).
NoV VLP binding to D-Caco-2 cells
VLPs of all three GII.4 variants bound to D-Caco-2 cells.
Binding was not uniform across the entire cell prepar-
ation, and VLPs could be detected only on certain cells
or clusters of the cell layer. As an example, fluorescence
microscopy images showing the attachment of 2004 vari-
ant NoV VLPs (v2) to D-Caco-2 cells are shown in Fig. 5.
No signals were detected in any of the negative controls
without VLPs.
Fig. 1 Binding of NoV VLPs (GII.4-1999 (v0) and GII.4-2004 (v2) and
GII.4-2006b) to porcine gastric mucin (PGM). Microtiter plates coated
with PGM (10 μg/ml) or without PGM (PBS) were incubated with the
different VLPs at 2 μg/ml for 1 h and processed for detection of bound
VLPs by ELISA, using an anti-NoV VLP rabbit polyclonal antiserum
(pAb). Binding is expressed as percentages referred to the highest OD
450 nm value obtained in duplicate assays. Error bars indicate
standard deviations
Fig. 2 Mean values of NoV VLP binding to saliva samples expressed
as percentages. NoV VLPs (G1.1, GII.4-v0, GII.4-v2 and GII.4-2006b)
were assayed for their ability to bind to saliva samples from 22
volunteers including non-secretors (n = 3) and secretors with blood
group A (n = 8), B (n = 4) and O (n = 7). Error bars indicate standard
deviations. P values indicating significant differences between NoV
VLP binding are shown
Carmona-Vicente et al. Virology Journal  (2016) 13:82 Page 3 of 12
Blockade of VLP binding to D-Caco-2 cells
Anti-NoV mAbs used in this study strongly blocked the
attachment of NoV VLPs to the surface of D-Caco-2
cells, and with the same strain-specificity as that ob-
served in the salivary assays. Consistent with the ELISA
results, a 74 % binding reduction was observed when
VLPs were pre-incubated with the av2.mAb prior to
adding to the cells (Fig. 6a). The blocking activity of the
av0.mAb was of 82 %, whereas anti-2006b mAb also
blocked the VLP binding (54.5 % reduction) (Table 2).
When the VLPs were incubated with different PGM con-
centrations, blockade of NoV VLPs binding to the D-
Caco-2 cells occurred in a dose-dependent manner. At a
concentration of 10 μg/ml, PGM completely abolished
the ability of NoV VLPs to bind to D-Caco-2 cells. PGM
at a concentration of 1 μg/ml caused a 50 % reduction
of VLPs bound to the cells, and no blocking effect was
seen at a concentration of 0.1 μg/ml (data not shown).
Figure 6b shows the blockade by anti-v2.mAb of VLPs
binding to D-Caco-2 cells. Fluorescence intensity was
measured using the ImageJ software program, which
demonstrated a 94.5 % blocking activity.
Analysis of D-Caco-2 cells HBGA diversity reveals high
expression of H-type 2, Ley and Lex antigens
To determine if anti-Lewis (anti-Lea, Leb, Lex and Ley)
and/or anti-type H (H1 and H2) antigen mAbs could in-
fluence and block the VLP binding to D-Caco-2 cells,
the expression and distribution of these antigens on the
surface of the D-Caco-2 cells were investigated. The
majority of D-Caco-2 cells expressed H-type 2 antigen
on their surface. High expression of Ley and Lex antigens
was also observed, whereas Leb and H-type 1 antigens
were sparsely expressed (Fig. 7).
NoV VLPs bind to D-Caco-2 cells independently of Ley
and H-type 2 antigen expression
Preincubation of D-Caco-2 cells with anti-Lewis Ley and
anti-H-type 2 mAbs did not result in any relevant block-
ing of GII.4 binding to the D-Caco-2 cells. Blockade by
Fig. 3 Blockade of the NoV VLP binding to saliva from a secretor (SeSe) individual by monoclonal antibodies (mAbs) against human Lewis antigens.
Microtiter plates coated with saliva were preincubated with mAbs against Lea, Leb, Lex, Ley or with a combination of Lea+x or Leb+y antigens and then the
VLPs (GII.4-v0 and v2, GII.4-2006b and GI.1) were added. Graphs show the means of duplicate tests. Specific blocking of VLP binding was determined by
comparing the percentage of reduction of the OD values in wells with mAbs compared to wells without mAbs. Error bars indicate standard
deviations of the means
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these antibodies was tested because of the high expres-
sion of Ley and H-type 2 antigens on the surface of D-
Caco-2 cells. Furthermore, HBGA expression did not
co-localise with the VLP binding, as it is shown as an
example in Fig. 8 with GII.4-2004 (v2) VLPs and the
H-type 2 antigen.
Discussion
HBGAs are neutral carbohydrates which are present on
the surface of erythrocytes and mucosal epithelial cells,
or as free oligosaccharides in milk, saliva and intestinal
fluid of secretor individuals [27]. They are synthesized
by sequential enzymatic transfer of single carbohydrate
residues to specific precursor carbohydrate substrates,
with very high genetic polymorphism [28]. Previous stud-
ies suggested that HBGAs are likely to play an important
role as cell receptors for NoV attachment [29, 30],
although the molecular mechanism leading to cell entry
and infection are to date largely unknown.
NoV binding assays using salivary EIAs have in recent
years become the technique of choice for the study of
the binding specificities of NoVs to HBGAs, since saliva
samples containing different HBGA expression profiles
are easy to collect, and the methods are relatively simple
and fast to perform. Moreover, assays using synthetic
HBGA have proven to be challenging in terms of repro-
ducibility, but also troublesome due to the unavailability
or difficulties in obtaining such reagents. In the absence of
a reliable cell culture system or an appropriate animal
model for human noroviruses, the NoV VLPs and HBGA
binding assays have contributed significantly to our
understanding of host susceptibility to NoV infection and
have also allowed the mapping of regions responsible
for the interaction between HBGAs and the P2 sub-
domain [10, 31, 32].
In this study we have identified the HBGA binding
profiles of four different NoV VLPs representing gen-
ogroups I (GI.1) and II (GII.4-1999 (v0), GII.4-2004 (v2)
and GII.4-2006b) using saliva samples from different
individuals. Four different binding patterns based on the
secretor status, blood type and Lewis phenotype have
previously been described [9, 30]. The VLPs used in this
study exhibited distinct HBGA binding patterns: GI.1
VLPs bound more efficiently to saliva type A and O than
to saliva type B, GII.4-v0 and v2 variant VLPs bound to
all types A, B and O, and GII.4-2006b VLPs bound most
efficiently to saliva type B. These results are in agree-
ment with those reported by Uusi-Kerttula et al. [21],
who analysed the binding of different NoV genotypes
and GII.4 variants to salivary and synthetic HBGAs.
While many studies have compared results of binding
assays to saliva and to synthetic HBGAs, the present
study also compares NoV VLP binding patterns to saliva
and to the human intestinal cell line Caco-2. Polarized
or D-Caco-2 cells are also known to be a useful tool for
the study of NoV binding, as both native NoVs and
VLPs bind and penetrate the cell surface despite their
inability to lead to productive infection [22, 33–35]. We
have used Caco-2 cells to understand host-virus interac-
tions because it has been demonstrated that they can
differentiate in culture into cells with high homology to
mature enterocytes in the intestinal epithelium [36, 37].
Moreover, they express HBGAs, like Lewis or H-type
antigens [17, 22, 38].
Fig. 4 Blockade with anti-NoV mAbs of VLP binding to saliva samples. Microtiter plate wells were coated with saliva from a secretor individual at
1:500. Each VLP variant was preincubated with its homologous mAb before being added to the plate at 37 °C and detected with HRP-conjugated
to anti-mouse IgG. All dilutions of anti-NoV antibodies reduced the binding with the homologous VLP variant compared to the controls in a
dose-dependent manner. Error bars represent standard deviation
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Our experiments with D-Caco-2 cells clearly demon-
strated that VLPs bound to certain subpopulations of
cells, and anti-NoV antibodies abolished binding to these
cells. We performed the VLP binding assays to D-Caco-2
cells at 37 °C, likely to represent physiological conditions
more accurately. Previous work has been performed
at 4 °C to prevent internalization which was reported
to occur in 5-7 % of the cells when incubating at 37 °C
[35]. However, similar internalisation has also been
reported even when incubation is performed at 4 °C [22].
Using HBGA-specific mAbs to localise HBGAs on the
surface of D-Caco-2 cells showed widespread expression
of H2 and Ley, and more diffuse or clustered expression
of H1, Leb and Lex. Our observations are similar to those
previously reported by Murakami et al. [22], and con-
trast with others reporting a high type H1 antigen ex-
pression [38]. However, Caco-2 are a heterogeneous cell
population and the expression of morphological and
functional characteristics depend on the degree of differ-
entiation, which may explain the different results ob-
served in relation to HBGA antigen expression, making
it difficult to compare results obtained by different la-
boratories. Blocking HBGA on the surface of D-Caco-2
cells with specific mAbs did not affect NoV VLP bind-
ing, furthermore, no co-localisation of HBGA and NoV
VLPs was observed by immunofluorescence. These re-
sults therefore suggest that binding to Caco-2 cells could
be mediated by receptors other than HBGAs, in agree-
ment with a recent report by Murakami et al. [22]. Some
viruses require interactions with more than one cellular
surface molecule to initiate their replication cycle, for
example bovine herpesvirus [39], and adenovirus [40].
Furthermore, some NoV strains, such as GII.4-2004, fail
to bind efficiently to any HBGA suggesting they may
bind other carbohydrates [41, 42], e.g. negatively charged
sugars, similar to feline calicivirus (FCV) [43] or murine
A
B
Fig. 5 Fluorescence microscopy analysis of the attachment of the GII.4 2004 variant NoV VLPs (v2) to D-Caco-2 cells. a Representative
immunofluorescence microscopy images of D-Caco-2 cells in the presence of 5 μg/ml of v2 VLPs (left). Binding of VLPs (shown a v2 strain) was
performed by incubating D-Caco-2 cells with VLPs followed by detection using an anti-NoV polyclonal antibody as described under the ‘Methods’
section. The arrow indicates VLP binding and numbers mark off the cells bound by v2 VLPs. Negative controls correspond to D-Caco-2 cells incubated
without VLPs (right). The image on the middle shows the cell monolayer under DAPI filter. b Mean counts of nine microscopic fields (40X) with
standard deviations of D-Caco-2 cells bound with NoV GII.4-v0, GII.4-v2 and GII.4-2006bVLPs (fluorescent cells/microscopic field). P values indicating
significant differences are shown
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norovirus (MNV) [44]. Specifically, FCV attach to a α 2,
6-linked sialic acid residue, but uses the junctional adhe-
sion molecule 1 (JAM-1) for internalization into host
cells [45]. Murine norovirus, in contrast, binds to a
ganglioside GD1a present on the surface of murine mac-
rophages [44]. In support of these hypotheses, some
studies have demonstrated binding of GII noroviruses to
negatively charged heparan sulfate [34], sialylated Lewisx
carbohydrate [46], H-type 3 antigen [21] and ganglio-
sides [47]. Furthermore, studies have shown that HBGA
association is not sufficient to overcome the failure to
propagate these viruses in vitro, as exemplified by the
resistance to infections of cell lines expressing HBGAs
[23, 48]. It must be acknowledged that the expression
and potential role of other HBGAs such as H3 and
H4 was not investigated here, and this requires fur-
ther study.
We propose that the D-Caco-2 cell binding assays may
be more suitable for studying in vitro human NoV at-
tachment and virus-host interactions than the salivary
assays, which may only be considering the HBGA-NoV
interactions, and are also likely to provide a more
reliable surrogate for neutralising assays.
Conclusions
The interaction of NoV GII.4 genotype variants VLPs
with human secretor positive saliva samples and with
D-Caco-2 cells is mediated by different attaching
receptors. Although their binding to saliva occurs
according to distinct HBGA binding patterns and can
be blocked by antibodies against Lewis antigens, their
attachment to D-Caco-2 cells may be dependent on
other receptors, which still need further investigation.
Methods
Recombinant NoV VLP expression
Copy DNA derived from capsid genes of NoV strains GI.1
and GII.4-Den Haag_2006b were cloned and expressed by
the Bac-to-Bac baculovirus expression system (Invitrogen,
A
B
Fig. 6 Blockade of binding of NoV VLPs to D-Caco-2 cells by anti-NoV mAbs. a (a) D-Caco-2 cells were incubated with GII.4-2004 variant (v2) VLPs.
(b) Same concentration of VLPs was pre-incubated with the homologous variant-specific mAb (at 1:100 dilution of the antibody) and added to
D-Caco-2 cells; (c) negative control incubated with PBS. b Measurement using the ImageJ software program of the fluorescence intensity revealing
NoV VLPs (v2) bound to D-Caco-2 cells and its blockade by anti-v2.mAb
Table 2 VLP binding blockade by NoV GII.4 variant-specific
mAbs
NoV GII.4 variant VLP binding to D-Caco-2 cellsa
mAb GII.4 1999 (v2) GII.4-2004 (v0) GII.4-2006b
none 23 ± 5 17 ± 2 22 ± 3
av2 mAb 6 ± 2 (74 %) - -
av0 mAb - 3 ± 1 (82 %) -
3C3G3 mAb - - 10 ± 2 (54.5 %)
a Mean values ± SD of fluorescent cell counts in ten microscopic fields (40X).
The blocking of VLP binding to D-Caco-2 cells was performed with mAbs by
preincubating the different VLPs for 1 h with the test antibodies diluted to
1:100 in PBS or with PBS alone for the negative control. Blocking percentages
are indicated between parentheses
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Paisley, UK), and recombinant NoV VLPs were pro-
duced in Sf9 insect cells following described procedures
[49]. VLPs were purified from the cellular fraction lysed
with Triton X-100 and centrifuged through a 40 % (w/
v) sucrose cushion. VLPs of strains GII.4-1999 (v0) and
GII.4-2004 (v2) were also expressed by recombinant
baculoviruses as previously described [13]. The three
GII.4 variants were chosen by their reported distinct
binding properties [15, 50]. The different NoV VLP
preparations were examined by electron microscopy
(EM) after negative staining with 2 % phosphotungstic
acid for purity, morphology and integrity appraisal.
Fig. 8 NoV VLPs bind to D-Caco-2 cells independently of H type-2 antigen expression. GII.4-2004 (v2) VLPs were added to D-Caco-2 cells after
adding anti-H2 antigen. After 1 h incubation at 37 °C with an anti-H2 mAb, the cells were fixed and incubated with secondary FITC-conjugated
anti-rabbit IgG (to detect VLP binding) or Texas red-conjugated anti-mouse IgG (to detect anti-H2) antibodies. No co-localization of H2 antigen
expression and VLP binding was observed
A
B
Fig. 7 Heterogeneous expression of HBGAs on D-Caco-2 cell surface. a Immunofluorescence assay on D-Caco-2 cells fixed with methanol. Lewis
and H antigens were detected by anti-Lea (images not shown), Leb, Lex, Ley, H1 and H2 antibodies, followed by FITC-labeled anti–mouse IgG. Cells
were counterstained with Evans blue (red fluorescence). HBGA expression in D-Caco-2 cells was evaluated by counting immunofluorescent cells
in 10 microscopic fields (40X). (a and d) Weak expression of both Leb and H1 antigen (score 1+), respectively. (b and c) Strong expression of Lex
and Ley (score 2+). (e) Very strong H2 antigen expression on D-Caco-2 cell surface (score 3+). b Mean counts of 10 microscopic fields (40X) with
standard deviations of D-Caco-2 cells immunostained with anti-Lea, Leb, Lex, Ley, H1 and H2 antibodies (fluorescent cells/microscopic field). All
differences were statistically significant (p < 0.01)
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Saliva samples
Saliva samples were collected from 22 healthy adult
volunteers, none of whom had taken any medication at
the time or around the time of sample collection. To
minimize the effects of the circadian rhythm, saliva
samples were consistently collected in the morning
hours (between 8 and 10 a.m.). Also, participants were
instructed not to smoke, eat, drink, or brush their teeth
in the 2 h before saliva collection. Freshly collected
saliva samples were centrifuged at 10,000 × g for 5 min
to remove particulate material, host and microbial cells
and boiled at 100 °C to inactivate antibodies. Superna-
tants were collected, divided into several aliquots and
stored at -80 °C until their use. Blood ABO typing of the
saliva donors was performed by hemagglutination assays
(ALBAclone® Monoclonal ABO Antisera, Alpha Labora-
tories, Eastleigh, England). Lewis antigens were pheno-
typed in the saliva samples by ELISA with monoclonal
antibodies against Lea, Leb, Lex and Ley (Covance, Ded-
ham, MA, USA). Briefly, plates were coated with saliva
samples at 1:1000 dilution in carbonate/bicarbonate buf-
fer (pH 9.6) at 4 °C overnight. After blocking with PBS
containing 3 % (w/v) bovine seroalbumin (PBS-BSA),
plates were incubated with the different anti-Lewis anti-
gen monoclonal antibodies (anti-Lea BG-5, Leb BG-6,
Lex BG-7 or Ley BG-8, Covance) at 1:100 during 1 h at
37 °C and detected by a secondary mouse antibody mix
(anti-IgG, anti-IgM and anti-IgA) (Sigma) conjugated to
horseradish peroxidase (HRP). After each step, plates
were washed with PBS containing 0.05 % of Tween-20
(PBS-T). The reaction was developed by the addition of
OPD Fast (Sigma, Dorset, England) and stopped after
10 min incubation with 3 M H2SO4. Absorbance was
measured at 492 nm in a microplate reader (Multiskan
FC, Thermo Scientific, Vantaa, Finland).
The secretor (FUT2+) and non-secretor (FUT2-)
status was investigated by genotyping the FUT2 gene.
Genomic DNA was extracted from saliva samples
using the Qiagen QIAamp DNA Mini Kit. Genotyping
for FUT2 was performed by PCR-RFLP as described
previously [51].
Monoclonal (mAb) and polyclonal (pAb) antibody
production
BALB/c mice were immunized by intraperitoneal (IP)
inoculation of three doses of GII.4-2006b VLPs with
Freund’s adjuvant at 15-day intervals. Splenocytes were
fused with Sp2/0-Ag14 mieloma cells as described previ-
ously [52] and hybridomas were screened by ELISA
using the same NoV VLP genotype as the antigen. An
anti-GII.4-2006b was obtained (3C3G3) and used along
the present study. The anti-v0.mAb and anti-v2.mAb
were previously obtained as described [13]. A polyclonal
antiserum (pAb) against NoV VLPs was obtained at
the Public Health England (PHE, London) by immunizing
rabbits with a mixture of VLPs (GII.4-v0, GII.4-v2
and GII.3).
Enzyme-linked immunoassays (EIAs)
VLP binding to porcine gastric mucin (PGM)
Microtiter plates were coated with PGM at 10 μg/ml in
carbonate-bicarbonate buffer (pH 9.6) at 37 °C over-
night. Plates were washed three times with PBS-T (PBS
containing 0.05 % Tween-20), blocked with PBS contain-
ing 1 % skimmed milk and incubated 30 min at 37 °C.
VLPs were added at 2 μg/ml in PBS and incubated 1 h
at 37 °C. After three washes, the anti-VLPs rabbit
polyclonal antiserum (pAb) was added at 1:1000 dilu-
tion. Binding was detected with HRP-conjugated anti-
rabbit IgG at 1:10,000 dilution (Bioss, Woburn, MA).
The reaction was developed by the addition of TMB
(3,3’,5,5’-tetramethyl-benzidine, Sigma) and stopped after
10 min incubation with 4 N H2SO4. Absorbance was
measured at 450 nm in a microplate reader Multiskan
FC (Thermo Scientific). Negative and blank controls
were included in all assays.
Blocking assays
The same EIA protocol used to measure NoV VLP bind-
ing to HBGAs in saliva was followed as described [9],
adding an incubation step with the different mAbs
before the addition of the VLPs, and/or preincubating
the VLPs in the presence of the NoV-specific antibodies.
Monoclonal antibodies against Lewis antigens were
added to the plate at a dilution of 1:10. NoV VLPs (GI.1,
GII.4-2006b, GII.4-v0 and GII.4-v2) were added at 2-
10 μg/ml depending of the VLP variant, and their detec-
tion was performed with the anti-NoV rabbit polyclonal
serum followed by a secondary HRP-conjugated anti-
rabbit IgG antibody diluted at 1:10,000 (Bioss, Woburn,
MA). The ability of anti-NoV mAbs to block the binding
of VLPs to saliva was tested using serial 2-fold dilutions of
each mAb from 1:100 until 1:3200. The VLPs (2 μg/ml
in PBS) were pre-incubated with the assayed antibodies,
or with PBS in the negative control, for 1 h at 37 °C.
The mixtures were then added to the saliva-coated
plates and incubated for 1 h at 37 °C. The binding
of VLPs was determined by incubation with HRP-
conjugated anti rabbit or anti-mouse IgG antibodies
(1:2000 dilution), as appropriate, followed by the
peroxidase substrate TMB step.
Blocking of binding to PGM was determined using
the assay format described, but coating with PGM
(5 μg/ml) the microtiter plates. Blocking of VLP bind-
ing by the tested antibodies was determined by com-
paring the OD values obtained in wells in duplicate
containing potential blocking reagents against the
control wells (without the blocking steps).
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Caco-2 cell binding assays
Caco-2 cell culture
Caco-2 cells were grown in Dulbecco’s modified Eagle’s
minimum essential medium (DMEM) (Invitrogen) sup-
plemented with 4.5 % glucose, 10 % (v/v) fetal bovine
serum (Invitrogen), non-essential amino acids, 100 I.U./
ml penicillin, 100 mg/ml streptomycin, 2 mM glutam-
ine and 1 mM sodium pyruvate, at 37 °C under a
humidified atmosphere with 5 % CO2. Binding medium
(BM), used when the cells were incubated with the
VLPs, contained all of the above except fetal bovine
serum.
Cell binding assays
Caco-2 cell binding assays were perfomed as previously
described [17] with modifications. Caco-2 cells were
seeded at 2 × 105 cells/ml on culture slides (BD Falcon,
Bedford, MA). Cells were cultured for 9-10 days to allow
cell differentiation (D-Caco-2). D-Caco-2 cells were
washed twice with PBS and incubated with VLPs (5 μg/
ml) in 200 μl BM at 37 °C for 1 h, under a humidified at-
mosphere. Negative controls consisted of cells incubated
without VLPs. After 3 washes with PBS, cells were fixed
with methanol for 15 min at room temperature and then
blocked with PBS containing 1 % skimmed milk (PBS-
milk 1 %) for 30 min at 37 °C. Fixed cells were subse-
quently incubated at 37 °C for 1 h with polyclonal rabbit
IgG anti-NoV VLPs (PHE) antibody at 1:4000 dilution in
PBS. After washing the cells with PBS-0.05 % Tween-20,
they were incubated with a goat FITC-conjugated anti-
rabbit IgG antibody (Abcam, Cambridge, UK) at 1:1000
dilution for 1 h at 37 °C. Finally, slides were mounted
with 10 % glycerol in saline and preparations were
observed under a Nikon Eclipse 80i fluorescence micro-
scope equipped with a digital camera and the Hamamatsu
camera controller C4742-95 (Hamamatsu City, Japan).
Expression of HBGAs
Immunofluorescence assays were performed as descr-
ibed above in order to analyse the expression of Lewis
antigens, using anti-Lea BG-5, Leb BG-6, Lex BG-7 and
Ley BG-3 monoclonal antibodies (Covance) and anti-H
antigens (mAb to blood group H1(O) and anti-blood
group H2 antigen, Abcam). Anti-Lewis antigen mAbs
were used diluted to 1:100 and anti-H antigens mAbs
to 1:200. For visualization, a secondary antibody
FITC-conjugated anti-mouse IgG antibody (Santa Cruz
Biotechnology) diluted 1:400 was used. HBGA expression
in D-Caco-2 cells was evaluated by counting immuno-
fluorescent cells in 10 microscopic fields (40X). A semi-
quantitative four stage scoring system was applied with
the following ranges: negative (-); < 50 fluorescent cells
(1+); 51-199 fluorescent cells (2+), and >200 fluorescent
cells (3+).
VLP-cell binding blocking assays
To assess the ability of anti-HBGA-specific antibodies
to block the binding of VLPs to D-Caco-2 cells, cell
chambers were incubated with anti-Ley or anti-H-type
2 mAbs (as described for the HBGA expression assay)
prior to incubation with the NoV GII.4-v2 VLPs. In
order to study the ability of the anti-NoV antibodies
to block the binding of the NoV VLPs to D-Caco-2
cells, VLPs were incubated with their homologous
antibody using the same conditions as in the salivary
blocking assays, but with BM as the diluent. Blocking
of VLPs binding to D-Caco-2 cells by PGM was
performed by incubating the GII.4-v2 VLPs for 1 h at
37 °C with PGM at a concentration of 0, 10 and
50 μg/ml. The rest of the procedure was described in
the binding assays section. Control cells were incu-
bated with buffer instead of mAbs/VLP, and VLPs in
the absence of mAbs or PGM were used as positive
binding controls. Staining specificity was assessed in
negative controls by (1) omission of the VLP step and
(2) replacement of primary antibodies with 3 % BSA/
PBS. Immunofluorescence was assessed on a quantita-
tive scale by calculating the number of positive cells
on each well chamber in 10 microscopic fields (40X).
Fluorescence intensity of the VLP-cell binding and
blocking assays was measured using the Java-based
image processing ImageJ 1.49 program [53].
Statistical analysis
The nonparametric Mann-Whitney test was applied to
determine the presence or absence of significant differ-
ences. In all cases p-values below 0.05 were considered
statistically significant. The analyses were performed by
using the IBM SPSS software vs. 22.0 (IBM Corp.).
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